Literature DB >> 22107829

Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

Mariko Watanabe1, Kinji Itoh, Tomiteru Togano, Marshall E Kadin, Toshiki Watanabe, Masaaki Higashihara, Ryouichi Horie.   

Abstract

Overexpression of CD30 and JunB is a hallmark of tumor cells in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). We reported that CD30-extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) signaling induces JunB, which maintains constitutive activation of the CD30 promoter. Herein, we localize a cis-acting enhancer in the JunB promoter that is regulated by Ets-1. We show that E26 transformation-specific-1 (Ets-1) (-146 to -137) enhances JunB promoter activation in a manner that is dependent on CD30 or the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-ERK1/2 MAPK pathway. Ets-1 knockdown reduces the expression of both JunB and CD30, and CD30 knockdown significantly reduces JunB expression in HL and ALCL cell lines. NPM-ALK knockdown also reduces JunB expression in ALCL cell lines expressing NPM-ALK. Collectively, these results indicate that CD30 and NPM-ALK cooperate to activate the ERK1/2 MAPK-Ets-1 pathway. Ets-1, constitutively activated by ERK1/2-MAPK, plays a central role in the overexpression of JunB and CD30, which are both involved in the pathogenesis of HL and ALCL.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22107829      PMCID: PMC4429177          DOI: 10.1016/j.ajpath.2011.10.007

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

Review 1.  Signal transduction and the Ets family of transcription factors.

Authors:  J S Yordy; R C Muise-Helmericks
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

2.  The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.

Authors:  Ryouichi Horie; Mariko Watanabe; Takaomi Ishida; Tsukasa Koiwa; Shigemi Aizawa; Kinji Itoh; Masaaki Higashihara; Marshall E Kadin; Toshiki Watanabe
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

3.  Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  Mariko Watanabe; Yuji Ogawa; Kinji Itoh; Tukasa Koiwa; Marshall E Kadin; Toshiki Watanabe; Isao Okayasu; Masaaki Higashihara; Ryouichi Horie
Journal:  Lab Invest       Date:  2007-10-29       Impact factor: 5.662

Review 4.  AP-1 in mouse development and tumorigenesis.

Authors:  W Jochum; E Passegué; E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

5.  AP-1--Introductory remarks.

Authors:  E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

6.  junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2.

Authors:  P Coffer; M de Jonge; A Mettouchi; B Binetruy; J Ghysdael; W Kruijer
Journal:  Oncogene       Date:  1994-03       Impact factor: 9.867

7.  IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.

Authors:  Mariko Watanabe; Md Zahidunnabi Dewan; Miyako Taira; Momoko Shoda; Mitsuo Honda; Testutaro Sata; Masaaki Higashihara; Marshall E Kadin; Toshiki Watanabe; Naoki Yamamoto; Kazuo Umezawa; Ryouichi Horie
Journal:  Lab Invest       Date:  2007-02-19       Impact factor: 5.662

8.  Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells.

Authors:  Nagarajan Selvamurugan; Sukyee Kwok; Nicola C Partridge
Journal:  J Biol Chem       Date:  2004-04-14       Impact factor: 5.157

9.  Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation.

Authors:  B Li; C Tournier; R J Davis; R A Flavell
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

10.  A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages.

Authors:  R Horie; K Ito; M Tatewaki; M Nagai; S Aizawa; M Higashihara; T Ishida; J Inoue; H Takizawa; T Watanabe
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

View more
  9 in total

1.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

Review 2.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

3.  CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Wenli Zheng; L Jeffrey Medeiros; Ying Hu; Linda Powers; Jorge E Cortes; Farhad Ravandi-Kashani; Hagop H Kantarjian; Sa A Wang
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-01-10

4.  Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.

Authors:  V Atsaves; R Zhang; D Ruder; Y Pan; V Leventaki; G Z Rassidakis; F X Claret
Journal:  Leukemia       Date:  2015-05-19       Impact factor: 11.528

Review 5.  The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Authors:  Ines Garces de Los Fayos Alonso; Huan-Chang Liang; Suzanne D Turner; Sabine Lagger; Olaf Merkel; Lukas Kenner
Journal:  Cancers (Basel)       Date:  2018-03-28       Impact factor: 6.639

Review 6.  Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.

Authors:  Shinichi Makita; Dai Maruyama; Kensei Tobinai
Journal:  Onco Targets Ther       Date:  2020-06-23       Impact factor: 4.147

Review 7.  AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL.

Authors:  Zuoqiao Wu; Mary Nicoll; Robert J Ingham
Journal:  Exp Hematol Oncol       Date:  2021-01-07

8.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18

Review 9.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.